Leitlinien Chorea/Morbus Huntington für die deutschsprachigen Länder neu überarbeitet

The updated and revised guidelines (S2k level) on 'Chorea and Huntington's Disease (HD)' review the present understanding of the natural history of HD including rate of progression and describe new approaches to symptomatic and disease course-modifying therapies in HD. In contrast to other guidelines, the expert opinion in the German speaking countries favors tiapride as a first line treatment of chorea. Because of the side effect profile of tetrabenazine, including depression or akathisia, the authors prefer to use tetrabenazine as second line treatment. The current guidelines address medico-legal aspects of preimplantation genetic diagnosis (PGD) and prenatal testing in Germany, Austria and Switzerland as well as differences between a predictive and a diagnostic setting of molecular genetic diagnosis. In addition, the guidelines comment in detail on the differential diagnoses of a chorea of unknown origin.